エフルキシフェルミン薬は 肝硬変の治療に 有望な結果を示し 株価は93%増加しました Akero Therapeutics' Efruxifermin drug shows promise in reversing cirrhosis, boosting stock by 93%.

代謝機能障害関連ステアト肝炎 (MASH) の患者で,エフルキシフェルミンという薬が,第IIb相試験で,肝硬変の逆転に有意な効果を示した. Akero Therapeutics' drug Efruxifermin showed significant results in reversing cirrhosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a phase IIb trial. プラセボ群では15%の患者に対して39%の患者が肝硬変を逆転させたことが判明した. The study found that 39% of patients treated with the drug had reversed cirrhosis compared to 15% in the placebo group. 陽性の結果,Akeoの株式価格が50.54ドルに急上昇した. The positive results led to a 93.05% surge in Akero's stock price to $50.54 in pre-market trading.